Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis

Mokadem, Mostafa El; Elramly, Mohamed; Hassan, Amr; Boshra, Hesham; AbdelWahab, Amir

doi:10.1016/j.carrev.2017.05.018

Cited by 5 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This indicated that PES and PCB are equally effective at preventing said events in patients with coronary artery disease. This finding is consistent with the findings of a previous meta-analysis conducted by Li et al 26 , which concluded that drug-coated balloon is noninferior to drug-eluting stent in terms of delivering a good outcome in nonfatal myocardial infarction in patients with de novo small coronary artery vessel disease. Similar results were found in the meta-analysis performed by Elgendy et al 24 , which concluded that PCB was associated with similar risk of target vessel revascularization at 1-year follow up in patients with ISR.…”

Section: Discussionsupporting

confidence: 92%

“…Paclitaxel is lipophilic, thus allowing rapid, homogeneously distributed cellular uptake. In addition, the lipophilic properties of paclitaxel have prolonged effects on arterial smooth muscle cells 26 , 27 . This property provides a promising application for the coating of balloons in the treatment of CAD 27 .…”

Section: Introductionmentioning

confidence: 99%

“…The study showed an increased risk of TVR and TLR with PCB at extended follow-up compared to everolimus-eluting stents (EES), and better late angiographic outcomes with EES 24 . Paclitaxel is an antiproliferative agent that works de Liyis, Aryaweda & Suastika, GCSP 2024:12 by stabilizing the intracellular microtubules, preventing mitosis in the Go-G1 and G2-M phases of the cell cycle, and effectively preventing the prolonged smooth muscle cell proliferation that occurs during in-stent restenosis 25,26 . Paclitaxel is lipophilic, thus allowing rapid, homogeneously distributed cellular uptake.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Paclitaxel-eluting stents versus paclitaxel-coated balloons in coronary artery disease: a meta-analysis of randomized controlled trials

De Liyis,

Aryaweda,

Suastika

2024

gcsp

View full text Add to dashboard Cite

The efficacy of drug-coated balloons (DCB) versus drug-eluting stents (DES) for coronary artery disease (CAD) remains inconclusive. Despite paclitaxel's common use in both DES and DCB, there is a lack of meta-analyses comparing paclitaxel-eluting stents (PES) and paclitaxel-coated balloons (PCB). This meta-analysis aims to evaluate and compare DES and DCB outcomes using paclitaxel. A Systematic literature search in Medline and Cochrane databases yielded six randomized controlled trials with 951 patients (1:1 ratio). Primary endpoints were mortality, target lesion vascularization (TLV), myocardial infarction (MI), target vessel revascularization (TVR), and major adverse cardiovascular events (MACEs). Secondary endpoints included in-device binary stenosis, in-segment binary stenosis, late luminal loss (LLL), post minimal lumen diameter (MLD), and post diameter stenosis. Within the study populations, the incidence of previous MI was significantly lower in the PES group compared to the PCB group (26.70% vs. 39.22%, OR:0.56, 95%CI:0.41–0.76, p=0.0002). The meta-analysis results showed that mortality (OR:1.57, 95%CI:0.67-3.66, p=0.29), TLV (OR:0.74, 95%CI:0.37-1.48, p=0.39), MI (OR:1.76, 95%CI:0.79-3.88, p=0.16), TVR (OR:0.76, 95%CI:0.51-1.12, p=0.16), and MACEs (OR:1.11, 95%CI:0.48-2.58, p=0.81) did not exhibit significant differences between PES and PCB group in CAD. Furthermore, in stent or in balloon binary stenosis (OR:0.80, 95%CI:0.34-1.87, p=0.60), in segment binary stenosis (OR:1.16, 95%CI:0.48-2.80, p=0.74), LLL (MD:0.03, 95%CI:-0.11 to 0.17, p=0.65), post MLD (MD:0.04, 95%CI:-0.23 to 0.30, p=0.77), and post diameter stenosis (MD:-5.48, 95%CI:-13.88 to 2.92, p=0.20) were similar in both groups. Our comprehensive analysis concludes that both PES and PCB manifest comparable effectiveness and safety in the management of CAD.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Paclitaxel-eluting stents versus paclitaxel-coated balloons in coronary artery disease: a meta-analysis of randomized controlled trials

De Liyis,

Aryaweda,

Suastika

2024

gcsp

View full text Add to dashboard Cite

show abstract

“…1 In contrast to bare metal stents, drug-eluting stents (DESs) have been shown to cause a remarkable reduction in repeated revascularization. 2 However, several observational studies have confirmed that the risk of death or myocardial infarction (MI) remains after DES implantation. 3 Dual antiplatelet therapy (DAPT), which is a P2Y12 inhibitor, has been perceived as a way to prevent thrombus formation.…”

Section: Introductionmentioning

confidence: 99%

Duration of dual antiplatelet therapy in patients with acute coronary syndrome undergoing drug-eluting stent implantation: A meta-analysis

2020

View full text Add to dashboard Cite

Objective: This meta-analysis was performed to evaluate the optimal discontinuation of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation in acute coronary syndrome (ACS) patients. Methods: A systematic search was conducted without language restrictions using PubMed, the Cochrane Library, and Clinical Trials.gov from January 2008 to July 2019. Studies that met the following criteria were included: (1) randomized trials that compared DAPT durations of <12 months ("short DAPT") or 12 months ("long DAPT"); (2) studies that included data on patients with ACS; and (3) studies that included data on outcomes. The outcomes were pooled using the Mantel-Haenszel model, generating relative risk (RR) and 95% confidence intervals (CI). Statistical heterogeneity was evaluated using the Cochrane Q statistic P-value and I 2 value. Publication bias was assessed by visually inspecting the funnel plots. Results: Eight studies comprising 10,537 participants were included in the analysis. The primary endpoint was not different between short-term and long-term DAPT (RR, 1.11; 95% CI, 0.92-1.34). Conclusion: A meta-analysis of the available evidence suggests that DAPT can be reduced to 3 or 6 months without increasing the risk of cardiovascular and cerebrovascular events in patients with ACS who are undergoing DES implantation.

show abstract

A potential strategy for in-stent restenosis: Inhibition of migration and proliferation of vascular smooth muscle cells by Cu ion

Zhang

Wang

et al. 2020

Materials Science and Engineering: C

View full text Add to dashboard Cite

Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis

Cited by 5 publications

References 15 publications

Paclitaxel-eluting stents versus paclitaxel-coated balloons in coronary artery disease: a meta-analysis of randomized controlled trials

Paclitaxel-eluting stents versus paclitaxel-coated balloons in coronary artery disease: a meta-analysis of randomized controlled trials

Duration of dual antiplatelet therapy in patients with acute coronary syndrome undergoing drug-eluting stent implantation: A meta-analysis

A potential strategy for in-stent restenosis: Inhibition of migration and proliferation of vascular smooth muscle cells by Cu ion

Contact Info

Product

Resources

About